Digital Medicine
We work with founders to build companies leveraging AI, machine learning and data analytics to transform healthcare and medicine.
Our approach is evidence-based, rooted in rigorous scientific research and clinical validation and builds on Sofinnova's 50 years of experience in the life sciences sector.
| Close | Fund | AMT |
|---|---|---|
| 2023 | Sofinnova Digital Medicine I | $200 million |
Close: 2023
Fund: Sofinnova Digital Medicine I
AMT: $200 million
"We bring our experience in biological innovation coupled with powerful computing and AI capabilities to build deeply technical companies to product-market fit. This is what makes our approach unique."
"We designed this strategy to help founders leverage our knowledge of a highly-regulated and complex healthcare industry while drawing on the strengths of tech-industry approaches like rapid product iteration and swift commercialization."
The
Team
Companies
Fund iteration
Status
Deal lead
Related News
Bioptimus launches H-optimus-0, the world's largest open-source AI foundation model for pathology
Cure51 raises a €15 million seed round to harness the natural power of cancer survivors to develop first in class treatments and transform cancer into a curable disease
Signature of a partnership agreement with Kiro
Ex-Google DeepMind and Owkin scientists team up to create Bioptimus to build the first universal AI foundation model for biology
deepc acquires Osimis platform: strengthening the AI infrastructure for radiology at scale